In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...
Medtronic (NYSE:MDT), which has operations worldwide, is reportedly looking at adjusting its manufacturing footprint amid ...
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...
The latest health news reveals Medtronic's strategic response to U.S. tariffs, WHO's concerns on West Bank violence, mystery ...
Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...
Zacks.com on MSN3h
Top Stock Reports for Charles Schwab, Gilead Sciences & MedtronicToday's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), ...
A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback